Chilly Mazarin, France

Pierre Ferrandon

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Syntex (u.s.a.) Inc., Syntex Pharmaceuticals, Ltd.. Active years: 1996-1999.


% Patents Active = 100.0


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 1996-1999

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pierre Ferrandon: Innovator in Medical Treatments

Introduction

Pierre Ferrandon is a notable inventor based in Chilly Mazarin, France. He has made significant contributions to the field of medical treatments, particularly through his innovative work with piperazine derivatives. With a total of 2 patents, Ferrandon's inventions focus on addressing critical health issues.

Latest Patents

Ferrandon's latest patents include methods of treatment using ranolazine and related piperazine derivatives. These derivatives are particularly useful for treating tissues that experience physical or chemical insults. Specifically, they are designed to address conditions such as cardioplegia, hypoxic and/or reperfusion injury to cardiac or skeletal muscle, as well as brain tissue. Additionally, these methods are applicable in transplant scenarios, showcasing the versatility and importance of his work.

Career Highlights

Throughout his career, Ferrandon has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Syntex Inc. and Syntex Pharmaceuticals Ltd. His experience in these organizations has contributed to his expertise and innovative capabilities in developing medical treatments.

Collaborations

One of Ferrandon's notable collaborators is Robert J. Dow. Their partnership has likely fostered advancements in their respective fields, although specific details of their collaboration are not provided.

Conclusion

Pierre Ferrandon's contributions to medical treatments through his patents highlight his role as an innovator in the field. His work with piperazine derivatives has the potential to significantly impact patient care and treatment outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…